Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 9/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835757 | 0.85 | PARP1 (0.74) | PARP1PARP2HTTLMNAPOLB | |
| SCHEMBL19903083 | 0.81 | PARP1 (0.68) | PARP1PARP2HTTLMNAPOLB | |
| SCHEMBL1862798 | 0.78 | PARP1 (1.00) | PARP1PARP2HTTLMNA | |
| SCHEMBL12714874 | 0.78 | PARP1 (0.63) | PARP1PARP2HTTLMNAPOLB | |
| SCHEMBL834344 | 0.77 | PARP1 (1.00) | PARP1PARP2HTTLMNA | |
| SCHEMBL1867231 | 0.77 | PARP1 (0.76) | PARP1PARP2HTTLMNA | |
| SCHEMBL375101 | 0.76 | PARP1 (0.61) | PARP1PARP2HTTLMNA | |
| SCHEMBL1355339 | 0.76 | PARP1 (0.61) | PARP1PARP2HTTLMNA | |
| SCHEMBL6123445 | 0.76 | PARP1 (0.71) | PARP1PARP2HTTLMNA | |
| SCHEMBL24733343 | 0.76 | PARP1 (1.00) | PARP1PARP2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242302-A1 | COMBINATION THERAPY FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-12-21 | — | — | WO | disclosed |
| US-9789083-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9655881-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9518042-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-13 | — | — | US | disclosed |
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| US-8143284-B2 | 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBVIE INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | PARP1 3714/4885PARP2 4851/4885HTT 247/4885 |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | PARP1 4215/4885PARP2 4816/4885HTT 1113/4885 |
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885HTT 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.